Benedetta Puccini
About
Benedetta Puccini is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology.
According to data from OpenAlex, Benedetta Puccini has authored 56 papers receiving a total of 804 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pathology and Forensic Medicine, 19 papers in Neurology and 19 papers in Oncology. Recurrent topics in Benedetta Puccini's work include Lymphoma Diagnosis and Treatment (52 papers), CNS Lymphoma Diagnosis and Treatment (19 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Benedetta Puccini is often cited by papers focused on Lymphoma Diagnosis and Treatment (52 papers), CNS Lymphoma Diagnosis and Treatment (19 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Benedetta Puccini collaborates with scholars based in Italy, United States and Ukraine. Benedetta Puccini's co-authors include Luigi Rigacci, Alberto Bosi, Flavia Salvi, Luca Vaggelli, Annalisa Chiappella, Umberto Vitolo, Alberto Fabbri, Pier Luigi Zinzani, Barbara Botto and Marco Ladetto and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Benedetta Puccini
53 papers receiving 796 citations
Peers
Benedetta Puccini
Maria Giuseppina Cabras Italy
Flavia Salvi Italy
Reem Karmali United States
Allison Crosby‐Thompson United States
Gregory Bociek United States
Viola Poeschel Germany
Alden A. Moccia Switzerland
Evert-Jan G. Boerma Netherlands
Lorella Orsucci Italy
Christian W. Scholz Germany
Citations per year, relative to Benedetta Puccini Benedetta Puccini (= 1×)
peers
Maria Giuseppina Cabras
Countries citing papers authored by Benedetta Puccini
Since
Specialization
Citations
This map shows the geographic impact of Benedetta Puccini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benedetta Puccini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benedetta Puccini more than expected).
Fields of papers citing papers by Benedetta Puccini
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Benedetta Puccini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benedetta Puccini. The network helps show where Benedetta Puccini may publish in the future.
Co-authorship network of co-authors of Benedetta Puccini
This figure shows the co-authorship network connecting the top 25 collaborators of Benedetta Puccini. A scholar is included among the top collaborators of Benedetta Puccini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benedetta Puccini. Benedetta Puccini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Pinto, Antonio, et al.. (2025). A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy. ClinicoEconomics and Outcomes Research. Volume 17. 335–348.
2.
Linguanti, Flavia, Vittorio Miele, Francesco Mungai, et al.. (2024). Texture analysis of 18F‐FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement. Hematological Oncology. 42(2). e3261–e3261.
3.
Özcan, Muhıt, Eva González‐Barca, Tae Min Kim, et al.. (2024). Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma. Blood. 144(Supplement 1). 578–578.
4.
Arcari, Annalisa, Federica Cavallo, Benedetta Puccini, & Daniele Vallisa. (2023). New treatment options in elderly patients with Diffuse Large B-cell Lymphoma. Frontiers in Oncology. 13. 1214026–1214026.
5.
Barbetti, M., Flavia Linguanti, Francesco Mungai, et al.. (2023). Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques. Cancers. 15(7). 1931–1931.
6.
Cencini, Emanuele, Ilaria Romano, Lara Mannelli, et al.. (2023). Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network). Annals of Hematology. 102(4). 841–849.
7.
Capone, Manuela, Benedetta Peruzzi, Boaz Palterer, et al.. (2022). Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience. Translational Oncology. 26. 101552–101552.
8.
Skrypets, Tetiana, Cristina Ferrari, Luca Nassi, et al.. (2021). 18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis. Journal of Personalized Medicine. 11(2). 123–123.
9.
Liberati, Anna Marina, Luigi Rigacci, Benedetta Puccini, et al.. (2021). Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience. Clinical Lymphoma Myeloma & Leukemia. 22(3). 198–204.
10.
Luminari, Stefano, Benedetta Donati, Massimiliano Casali, et al.. (2019). A Gene Expression–based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. Clinical Cancer Research. 26(2). 373–383.
11.
Rigacci, Luigi, Benedetta Puccini, Alessandro Broccoli, et al.. (2019). Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. Annals of Hematology. 99(2). 283–291.
12.
Magi, Alberto, Marika Masselli, Angela Guerriero, et al.. (2019). The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma. Scientific Reports. 9(1). 8586–8586.
13.
Puccini, Benedetta, Luca Nassi, Carla Minoia, et al.. (2017). Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography. Annals of Hematology. 96(7). 1147–1153.
14.
Nobili, Stefania, Cristina Napoli, Benedetta Puccini, et al.. (2013). Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. Leukemia & lymphoma. 55(9). 2071–2078.
15.
Carella, Angelo Michele, Cármino Antônio De Souza, Stefano Luminari, et al.. (2012). Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leukemia & lymphoma. 54(1). 53–57.
16.
Zinzani, Pier Luigi, Luigi Rigacci, Vittorio Stefoni, et al.. (2011). Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. European Journal of Nuclear Medicine and Molecular Imaging. 39(1). 4–12.
17.
Rigacci, Luigi, Benedetta Puccini, Renato Alterini, et al.. (2011). Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients. Leukemia Research. 36(2). 182–185.
18.
Rigacci, Luigi, Benedetta Puccini, Lorenzo Iovino, et al.. (2011). Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma. Journal of Chemotherapy. 23(4). 227–231.
19.
Rigacci, Luigi, Alberto Fabbri, Benedetta Puccini, et al.. (2010). Oxaliplatin‐based chemotherapy (dexamethasone, high‐dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer. 116(19). 4573–4579.
20.
Rigacci, Luigi, Luca Nassi, Silvia Mappa, et al.. (2007). Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. Annals of Hematology. 86(8). 565–568.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maria Giuseppina Cabras Breakdown of academic impact, for papers by Flavia Salvi Breakdown of academic impact, for papers by Reem Karmali Breakdown of academic impact, for papers by Allison Crosby‐Thompson Breakdown of academic impact, for papers by Gregory Bociek Breakdown of academic impact, for papers by Viola Poeschel Breakdown of academic impact, for papers by Alden A. Moccia Breakdown of academic impact, for papers by Evert-Jan G. Boerma Breakdown of academic impact, for papers by Lorella Orsucci Breakdown of academic impact, for papers by Christian W. Scholz